Project Grant R01CA301129
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $679K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Hollywood, CA 90048, USA
Similar Awards
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $708,990 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded May 1, 2026, with a completion date of April 30, 2031. This five-year award supports fundamental research investigating the microenvironmental and cell type-specific regulation of colorectal cancer (CRC) metastasis by interleukin-17 (IL17). The research employs genetic models of IL17 receptor complex...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded Cedars-Sinai Medical Center a Project Grant of $662,610 on April 1, 2026, for research extending through March 31, 2031. The award supports the development and validation of universal methylated circulating tumor DNA (ctDNA) markers for minimal residual disease (MRD) detection and therapy response prediction in colorectal cancer. This research...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $695,634 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) on May 7, 2026, with a completion date of April 30, 2031. The research project investigates the role of interleukin-27 receptor (IL27R) signaling in B cell immune responses within the tumor microenvironment of hepatocellular carcinoma (HCC). The study seeks to identify novel biomarkers and...
- Federal Grant Award Summary The National Cancer Institute awarded a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) to J. David Gladstone Institutes, effective August 1, 2025, through May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The research addresses a critical gap in preclinical modeling by creating experimental frameworks that...
- Federal Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, with a completion date of April 30, 2031. This five-year research initiative will investigate the myeloid-stromal axis in colorectal cancer (CRC), specifically examining how interactions between macrophages and cancer-associated fibroblasts (CAFs) suppress anti-tumor immunity and promote tumor...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $191,700 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective September 1, 2025 through August 31, 2028. This award supports research investigating the etiology and tumor characteristics of early-onset pancreatic cancer. The project delivers two primary research products: (1) epidemiological analysis identifying modifiable risk factors associated with...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $733,864 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Beckman Research Institute of the City of Hope, effective June 1, 2026, through May 31, 2031. This five-year research initiative focuses on identifying and characterizing stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR) in tumor immunosurveillance. Using high-throughput CRISPR-based screening...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $637,509 Project Grant to the University of California, San Diego (UCSD) on May 11, 2026, under the Cancer Biology Research program (CFDA 93.396) to support a five-year research initiative extending through April 30, 2031. This award funds fundamental research investigating how cancer cells achieve signaling autonomy—the ability to sustain growth in nutrient- and growth factor-deprived environments—through rewiring of...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded UCSF a $724,840 Project Grant effective August 21, 2025, through July 31, 2030, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the relationship between persistent poverty and colorectal cancer risk through biological, behavioral, and place-based mechanisms. The research leverages existing data from two large population-based cohorts—the Multiethnic Cohort Study (MEC) and...